Thera-SAbDab

EMICIZUMAB

> Structural Summary

Therapeutic	Emicizumab
Target 1	F9
Heavy Chain 1	QVQLVQSGSELKKPGASVKVSCKASGYTFTDNNMDWVRQAPGQGLEWMGDINTRSGGSIYNEEFQDRVIMTVDKSTDTAYMELSSLRSEDTATYHCARRKSYGYYLDEWGEGTLVTVSS
Light Chain 1	DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK
100% seqID Fv 1 Structure	None
99% seqID Fv 1 Structure	None
95-98% seqID Fv 1 Structure	None
Target 2	F10
Heavy Chain 2	QVQLVESGGGLVQPGGSLRLSCAASGFTFSYYDIQWVRQAPGKGLEWVSSISPSGQSTYYRREVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARRTGREYGGGWYFDYWGQGTLVTVSS
Light Chain 2	DIQMTQSPSSLSASVGDRVTITCKASRNIERQLAWYQQKPGQAPELLIYQASRKESGVPDRFSGSRYGTDFTLTISSLQPEDIATYYCQQYSDPPLTFGGGTKVEIK
100% seqID Fv 2 Structure	None
99% seqID Fv 2 Structure	None
95-98% seqID Fv 2 Structure	None

There are currently no PDB structures close in sequence to either Fv of this therapeutic. Click the links to build models with ABodyBuilder: [Fv 1] [Fv 2]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder: [Fv 1] [Fv 2]
Test for possible therapeutic developability issues with TAP: [Fv 1] [Fv 2]
Assign canonical forms by sequence with SCALOP: [Fv 1] [Fv 2]
Number the sequences in any numbering scheme with ANARCI: [Fv 1 H] [Fv 1 L] [Fv 2 H] [Fv 2 L]

Format	Bispecific mAb
Isotype	G4;G4
Highest Clinical Trial (Jan '20)	Approved
Estimated Status (Jan '20)	NFD
Recorded Developmental Technology	na
INN Year Proposed	2015
INN Year Recommended	2016
Companies Involved	Chugai Pharmaceutical, Roche
Conditions Approved	Haemophilia A
Conditions Active	na
Conditions Discontinued	na
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]